XML 113 R40.htm IDEA: XBRL DOCUMENT
v3.22.4

Segmentation of key figures (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Statement [line items] |
Segmentation - Consolidated income statements | Segmentation – consolidated income statements
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations)1 |  | Group |
(USD millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |
Net sales to third parties |  | 41 296 |  | 41 995 |  | 9 249 |  | 9 631 |  |  |  |  |  | 50 545 |  | 51 626 |
Sales to other segments |  | 825 |  | 795 |  | 205 |  | 180 |  | -1 030 |  | -975 |  |  |  |  |
Net sales |  | 42 121 |  | 42 790 |  | 9 454 |  | 9 811 |  | -1 030 |  | -975 |  | 50 545 |  | 51 626 |
Other revenues |  | 1 249 |  | 1 179 |  | 28 |  | 61 |  | 6 |  | 11 |  | 1 283 |  | 1 251 |
Cost of goods sold |  | -11 569 |  | -11 751 |  | -4 978 |  | -5 147 |  | 1 061 |  | 1 031 |  | -15 486 |  | -15 867 |
Gross profit |  | 31 801 |  | 32 218 |  | 4 504 |  | 4 725 |  | 37 |  | 67 |  | 36 342 |  | 37 010 |
Selling, general and administration |  | -11 679 |  | -12 306 |  | -2 062 |  | -2 062 |  | -512 |  | -518 |  | -14 253 |  | -14 886 |
Research and development |  | -9 172 |  | -8 641 |  | -824 |  | -899 |  |  |  |  |  | -9 996 |  | -9 540 |
Other income |  | 531 |  | 1 149 |  | 103 |  | 233 |  | 171 |  | 470 |  | 805 |  | 1 852 |
Other expense |  | -2 695 |  | -1 732 |  | -273 |  | -397 |  | -733 |  | -618 |  | -3 701 |  | -2 747 |
Operating income |  | 8 786 |  | 10 688 |  | 1 448 |  | 1 600 |  | -1 037 |  | -599 |  | 9 197 |  | 11 689 |
(Loss)/income from associated companies |  | -2 |  | 5 |  | 2 |  | 2 |  | -9 |  | 15 332 |  | -9 |  | 15 339 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  | -837 |  | -811 |
Other financial income and expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 20 |  | -80 |
Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 371 |  | 26 137 |
Income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | -1 416 |  | -2 119 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 955 |  | 24 018 |
Attributable to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders of Novartis AG |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 955 |  | 24 021 |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | -3 |
Included in net income are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  | 379 |  | 71 |
Depreciation of property, plant and equipment |  | -837 |  | -859 |  | -204 |  | -210 |  | -122 |  | -139 |  | -1 163 |  | -1 208 |
Depreciation of right-of-use assets |  | -252 |  | -265 |  | -33 |  | -39 |  | -15 |  | -14 |  | -300 |  | -318 |
Amortization of intangible assets |  | -3 728 |  | -3 638 |  | -222 |  | -238 |  | -32 |  | -27 |  | -3 982 |  | -3 903 |
Impairment charges on property, plant and equipment, net |  | -407 |  | -271 |  |  |  | -9 |  |  |  | -1 |  | -407 |  | -281 |
Impairment of right-of-use assets |  | -3 |  |  |  |  |  |  |  |  |  |  |  | -3 |  |  |
Impairment charges on intangible assets, net |  | -1 299 |  | -367 |  | -25 |  | -28 |  | -2 |  | -8 |  | -1 326 |  | -403 |
Impairment charges and fair value changes on financial assets, net |  | -134 |  | 43 |  |  |  |  |  | -126 |  | -5 |  | -260 |  | 38 |
Additions to restructuring provisions |  | -1 069 |  | -240 |  | -40 |  | -62 |  | -259 |  | -26 |  | -1 368 |  | -328 |
Equity-based compensation of Novartis equity plans |  | -706 |  | -721 |  | -62 |  | -65 |  | -280 |  | -193 |  | -1 048 |  | -979 |
1 Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations)1 |  | Group |
(USD millions) |  | 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020 |  | 2021 |  | 2020 |
Net sales to third parties |  | 41 995 |  | 39 013 |  | 9 631 |  | 9 646 |  |  |  |  |  | 51 626 |  | 48 659 |
Sales to other segments |  | 795 |  | 792 |  | 180 |  | 189 |  | -975 |  | -981 |  |  |  |  |
Net sales |  | 42 790 |  | 39 805 |  | 9 811 |  | 9 835 |  | -975 |  | -981 |  | 51 626 |  | 48 659 |
Other revenues |  | 1 179 |  | 1 018 |  | 61 |  | 53 |  | 11 |  | 168 |  | 1 251 |  | 1 239 |
Cost of goods sold |  | -11 751 |  | -10 927 |  | -5 147 |  | -5 252 |  | 1 031 |  | 1 058 |  | -15 867 |  | -15 121 |
Gross profit |  | 32 218 |  | 29 896 |  | 4 725 |  | 4 636 |  | 67 |  | 245 |  | 37 010 |  | 34 777 |
Selling, general and administration |  | -12 306 |  | -11 657 |  | -2 062 |  | -2 076 |  | -518 |  | -464 |  | -14 886 |  | -14 197 |
Research and development |  | -8 641 |  | -8 118 |  | -899 |  | -862 |  |  |  |  |  | -9 540 |  | -8 980 |
Other income |  | 1 149 |  | 922 |  | 233 |  | 176 |  | 470 |  | 644 |  | 1 852 |  | 1 742 |
Other expense |  | -1 732 |  | -1 871 |  | -397 |  | -831 |  | -618 |  | -488 |  | -2 747 |  | -3 190 |
Operating income |  | 10 688 |  | 9 172 |  | 1 600 |  | 1 043 |  | -599 |  | -63 |  | 11 689 |  | 10 152 |
Income from associated companies |  | 5 |  | 1 |  | 2 |  | 2 |  | 15 332 |  | 670 |  | 15 339 |  | 673 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  | -811 |  | -869 |
Other financial income and expense |  |  |  |  |  |  |  |  |  |  |  |  |  | -80 |  | -78 |
Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | 26 137 |  | 9 878 |
Income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  | -2 119 |  | -1 807 |
Net income |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 018 |  | 8 071 |
Attributable to: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shareholders of Novartis AG |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 021 |  | 8 072 |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  | -3 |  | -1 |
Included in net income are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  | 71 |  | 91 |
Depreciation of property, plant and equipment |  | -859 |  | -912 |  | -210 |  | -282 |  | -139 |  | -124 |  | -1 208 |  | -1 318 |
Depreciation of right-of-use assets |  | -265 |  | -273 |  | -39 |  | -41 |  | -14 |  | -16 |  | -318 |  | -330 |
Amortization of intangible assets |  | -3 638 |  | -3 080 |  | -238 |  | -370 |  | -27 |  | -12 |  | -3 903 |  | -3 462 |
Impairment charges on property, plant and equipment, net |  | -271 |  | -324 |  | -9 |  | -116 |  | -1 |  |  |  | -281 |  | -440 |
Impairment charges on intangible assets, net |  | -367 |  | -768 |  | -28 |  | -141 |  | -8 |  | -5 |  | -403 |  | -914 |
Impairment charges and fair value changes on financial assets, net |  | 43 |  | 153 |  |  |  |  |  | -5 |  | 182 |  | 38 |  | 335 |
Additions to restructuring provisions |  | -240 |  | -217 |  | -62 |  | -98 |  | -26 |  | -39 |  | -328 |  | -354 |
Equity-based compensation of Novartis equity plans |  | -721 |  | -714 |  | -65 |  | -64 |  | -193 |  | -180 |  | -979 |  | -958 |
1 Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.
Segmentation - Consolidated balance sheets | Segmentation – consolidated balance sheets
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations)1 |  | Group |
(USD millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |
Total assets |  | 75 510 |  | 79 220 |  | 16 078 |  | 16 192 |  | 25 865 |  | 36 383 |  | 117 453 |  | 131 795 |
Total liabilities |  | -16 966 |  | -15 929 |  | -3 710 |  | -3 632 |  | -37 354 |  | -44 412 |  | -58 030 |  | -63 973 |
Total equity |  |  |  |  |  |  |  |  |  |  |  |  |  | 59 423 |  | 67 822 |
Net debt 2 |  |  |  |  |  |  |  |  |  | 7 245 |  | 868 |  | 7 245 |  | 868 |
Net operating assets |  | 58 544 |  | 63 291 |  | 12 368 |  | 12 560 |  | -4 244 |  | -7 161 |  | 66 668 |  | 68 690 |
Included in assets and liabilities are: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment |  | 8 488 |  | 9 168 |  | 1 861 |  | 1 901 |  | 415 |  | 476 |  | 10 764 |  | 11 545 |
Additions to property, plant and equipment 3 |  | 842 |  | 991 |  | 292 |  | 349 |  | 85 |  | 90 |  | 1 219 |  | 1 430 |
Total right-of-use assets |  | 1 233 |  | 1 349 |  | 90 |  | 104 |  | 108 |  | 108 |  | 1 431 |  | 1 561 |
Additions to right-of-use assets 3 |  | 196 |  | 222 |  | 31 |  | 26 |  | 20 |  | 73 |  | 247 |  | 321 |
Total goodwill and intangible assets |  | 51 357 |  | 53 919 |  | 9 230 |  | 9 603 |  | 358 |  | 255 |  | 60 945 |  | 63 777 |
Additions to goodwill and intangible assets 3 |  | 1 791 |  | 1 491 |  | 163 |  | 102 |  | 139 |  | 143 |  | 2 093 |  | 1 736 |
Total investment in associated companies |  | 107 |  | 170 |  | 9 |  | 7 |  | 27 |  | 28 |  | 143 |  | 205 |
Additions to investment in associated companies |  | 25 |  | 24 |  |  |  |  |  | 13 |  | 19 |  | 38 |  | 43 |
Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments |  |  |  |  |  |  |  |  |  | 18 930 |  | 28 329 |  | 18 930 |  | 28 329 |
Financial debts and derivative financial instruments |  |  |  |  |  |  |  |  |  | 26 175 |  | 29 197 |  | 26 175 |  | 29 197 |
Current income tax liabilities and deferred tax liabilities |  |  |  |  |  |  |  |  |  | 5 219 |  | 5 485 |  | 5 219 |  | 5 485 |
1 Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories
2 Note 29 provides additional disclosures related to net debt
3 Excluding the impact of business acquisitions
Net sales and total of selected non-current assets, by countries and regions |
|  | Net sales to third parties1 |  | Total of selected non-current assets2 |
(USD millions) |  | 2022 |  | % |  | 2021 |  | % |  | 2020 |  | % |  | 2022 |  | % |  | 2021 |  | % |
Country |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Switzerland |  | 970 |  | 2 |  | 873 |  | 2 |  | 800 |  | 2 |  | 23 708 |  | 32 |  | 25 770 |  | 33 |
United States |  | 17 653 |  | 35 |  | 16 818 |  | 33 |  | 16 484 |  | 34 |  | 35 353 |  | 48 |  | 37 054 |  | 48 |
France |  | 2 257 |  | 4 |  | 2 522 |  | 5 |  | 2 442 |  | 5 |  | 3 188 |  | 4 |  | 3 615 |  | 5 |
Germany |  | 4 278 |  | 8 |  | 4 870 |  | 9 |  | 4 518 |  | 9 |  | 2 229 |  | 3 |  | 2 378 |  | 3 |
China |  | 3 128 |  | 6 |  | 3 052 |  | 6 |  | 2 573 |  | 5 |  | 599 |  | 1 |  | 703 |  | 1 |
Japan |  | 2 205 |  | 4 |  | 2 683 |  | 5 |  | 2 804 |  | 6 |  | 165 |  |  |  | 217 |  |  |
Other |  | 20 054 |  | 41 |  | 20 808 |  | 40 |  | 19 038 |  | 39 |  | 8 241 |  | 12 |  | 7 351 |  | 10 |
Group |  | 50 545 |  | 100 |  | 51 626 |  | 100 |  | 48 659 |  | 100 |  | 73 483 |  | 100 |  | 77 088 |  | 100 |
Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe |  | 18 467 |  | 37 |  | 20 197 |  | 39 |  | 18 715 |  | 38 |  | 35 896 |  | 49 |  | 37 525 |  | 49 |
Americas |  | 21 536 |  | 42 |  | 20 463 |  | 40 |  | 19 725 |  | 41 |  | 35 806 |  | 49 |  | 37 522 |  | 49 |
Asia/Africa/Australasia |  | 10 542 |  | 21 |  | 10 966 |  | 21 |  | 10 219 |  | 21 |  | 1 781 |  | 2 |  | 2 041 |  | 2 |
Group |  | 50 545 |  | 100 |  | 51 626 |  | 100 |  | 48 659 |  | 100 |  | 73 483 |  | 100 |  | 77 088 |  | 100 |
1 Net sales to third parties by location of customer
2 Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets
Net sales by region | Segmentation – net sales to third parties Net sales to third parties by region1
|  | 2022 USD m |  | 2021 USD m |  | Change (2021 to 2022) USD % |  | 2020 USD m |  | Change (2020 to 2021) USD % |
Innovative Medicines |  |  |  |  |  |  |  |  |  |  |
Europe |  | 13 554 |  | 14 919 |  | -9 |  | 13 484 |  | 11 |
US |  | 15 899 |  | 14 999 |  | 6 |  | 14 342 |  | 5 |
Asia/Africa/Australasia |  | 8 929 |  | 9 304 |  | -4 |  | 8 718 |  | 7 |
Canada and Latin America |  | 2 914 |  | 2 773 |  | 5 |  | 2 469 |  | 12 |
Total |  | 41 296 |  | 41 995 |  | -2 |  | 39 013 |  | 8 |
Of which in Established Markets |  | 30 548 |  | 31 459 |  | -3 |  | 29 643 |  | 6 |
Of which in Emerging Growth Markets |  | 10 748 |  | 10 536 |  | 2 |  | 9 370 |  | 12 |
Sandoz |  |  |  |  |  |  |  |  |  |  |
Europe |  | 4 913 |  | 5 278 |  | -7 |  | 5 231 |  | 1 |
US |  | 1 754 |  | 1 819 |  | -4 |  | 2 142 |  | -15 |
Asia/Africa/Australasia |  | 1 613 |  | 1 662 |  | -3 |  | 1 501 |  | 11 |
Canada and Latin America |  | 969 |  | 872 |  | 11 |  | 772 |  | 13 |
Total |  | 9 249 |  | 9 631 |  | -4 |  | 9 646 |  | 0 |
Of which in Established Markets |  | 6 460 |  | 6 855 |  | -6 |  | 7 089 |  | -3 |
Of which in Emerging Growth Markets |  | 2 789 |  | 2 776 |  | 0 |  | 2 557 |  | 9 |
Group |  |  |  |  |  |  |  |  |  |  |
Europe |  | 18 467 |  | 20 197 |  | -9 |  | 18 715 |  | 8 |
US |  | 17 653 |  | 16 818 |  | 5 |  | 16 484 |  | 2 |
Asia/Africa/Australasia |  | 10 542 |  | 10 966 |  | -4 |  | 10 219 |  | 7 |
Canada and Latin America |  | 3 883 |  | 3 645 |  | 7 |  | 3 241 |  | 12 |
Total |  | 50 545 |  | 51 626 |  | -2 |  | 48 659 |  | 6 |
Of which in Established Markets |  | 37 008 |  | 38 314 |  | -3 |  | 36 732 |  | 4 |
Of which in Emerging Growth Markets |  | 13 537 |  | 13 312 |  | 2 |  | 11 927 |  | 12 |
1 Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
Other revenue | Segmentation – other revenue
|  | Innovative Medicines |  | Sandoz |  | Corporate (including eliminations) |  | Group |
(USD millions) |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |  | 2022 |  | 2021 |  | 2020 |
Profit-sharing income |  | 921 |  | 873 |  | 835 |  |  |  |  |  |  |  |  |  |  |  |  |  | 921 |  | 873 |  | 835 |
Royalty income |  | 28 |  | 74 |  | 107 |  | 18 |  | 24 |  | 25 |  | 6 |  | 11 |  | 168 |  | 52 |  | 109 |  | 300 |
Milestone income |  | 145 |  | 127 |  | 39 |  | 3 |  | 28 |  | 11 |  |  |  |  |  |  |  | 148 |  | 155 |  | 50 |
Other 1 |  | 155 |  | 105 |  | 37 |  | 7 |  | 9 |  | 17 |  |  |  |  |  |  |  | 162 |  | 114 |  | 54 |
Total other revenues |  | 1 249 |  | 1 179 |  | 1 018 |  | 28 |  | 61 |  | 53 |  | 6 |  | 11 |  | 168 |  | 1 283 |  | 1 251 |  | 1 239 |
1 Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.
Innovative Medicines |
Statement [line items] |
Net sales | Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands
|  | 2022 USD m |  | 2021 USD m1 |  | Change (2021 to 2022) USD % |  | 2020 USD m1 |  | Change (2020 to 2021) USD % |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |
Entresto |  | 4 644 |  | 3 548 |  | 31 |  | 2 497 |  | 42 |
Leqvio |  | 112 |  | 12 |  | nm |  |  |  | nm |
Total Cardiovascular |  | 4 756 |  | 3 560 |  | 34 |  | 2 497 |  | 43 |
Immunology |  |  |  |  |  |  |  |  |  |  |
Cosentyx |  | 4 788 |  | 4 718 |  | 1 |  | 3 995 |  | 18 |
Xolair 2 |  | 1 365 |  | 1 428 |  | -4 |  | 1 251 |  | 14 |
Ilaris |  | 1 133 |  | 1 059 |  | 7 |  | 873 |  | 21 |
Other |  | 1 |  |  |  | nm |  |  |  | nm |
Total Immunology |  | 7 287 |  | 7 205 |  | 1 |  | 6 119 |  | 18 |
Neuroscience |  |  |  |  |  |  |  |  |  |  |
Gilenya |  | 2 013 |  | 2 787 |  | -28 |  | 3 003 |  | -7 |
Zolgensma |  | 1 370 |  | 1 351 |  | 1 |  | 920 |  | 47 |
Kesimpta |  | 1 092 |  | 372 |  | 194 |  | 15 |  | nm |
Mayzent |  | 357 |  | 281 |  | 27 |  | 170 |  | 65 |
Aimovig |  | 218 |  | 215 |  | 1 |  | 164 |  | 31 |
Other |  | 1 |  | 1 |  | 0 |  |  |  | nm |
Total Neuroscience |  | 5 051 |  | 5 007 |  | 1 |  | 4 272 |  | 17 |
Solid Tumors |  |  |  |  |  |  |  |  |  |  |
Tafinlar + Mekinist |  | 1 770 |  | 1 693 |  | 5 |  | 1 542 |  | 10 |
Kisqali |  | 1 231 |  | 937 |  | 31 |  | 687 |  | 36 |
Votrient |  | 474 |  | 577 |  | -18 |  | 635 |  | -9 |
Lutathera |  | 471 |  | 475 |  | -1 |  | 445 |  | 7 |
Piqray |  | 373 |  | 329 |  | 13 |  | 320 |  | 3 |
Pluvicto |  | 271 |  |  |  | nm |  | 2 |  | nm |
Tabrecta |  | 133 |  | 90 |  | 48 |  | 35 |  | 157 |
Total Solid Tumors |  | 4 723 |  | 4 101 |  | 15 |  | 3 666 |  | 12 |
Hematology |  |  |  |  |  |  |  |  |  |  |
Promacta/Revolade |  | 2 088 |  | 2 016 |  | 4 |  | 1 738 |  | 16 |
Tasigna |  | 1 923 |  | 2 060 |  | -7 |  | 1 958 |  | 5 |
Jakavi |  | 1 561 |  | 1 595 |  | -2 |  | 1 339 |  | 19 |
Kymriah |  | 536 |  | 587 |  | -9 |  | 474 |  | 24 |
Adakveo |  | 194 |  | 164 |  | 18 |  | 105 |  | 56 |
Scemblix |  | 149 |  | 7 |  | nm |  |  |  | nm |
Other |  | 1 |  | 1 |  | 0 |  | 3 |  | -67 |
Total Hematology |  | 6 452 |  | 6 430 |  | 0 |  | 5 617 |  | 14 |
|  | 2022 USD m |  | 2021 USD m1 |  | Change (2021 to 2022) USD % |  | 2020 USD m1 |  | Change (2020 to 2021) USD % |
Other Promoted Brands |  |  |  |  |  |  |  |  |  |  |
Lucentis |  | 1 874 |  | 2 160 |  | -13 |  | 1 933 |  | 12 |
Xiidra |  | 487 |  | 468 |  | 4 |  | 376 |  | 24 |
Ultibro Group |  | 479 |  | 584 |  | -18 |  | 623 |  | -6 |
Beovu |  | 203 |  | 186 |  | 9 |  | 190 |  | -2 |
Other respiratory |  | 84 |  | 53 |  | 58 |  | 26 |  | 104 |
Total Other Promoted Brands |  | 3 127 |  | 3 451 |  | -9 |  | 3 148 |  | 10 |
Total Promoted Brands |  | 31 396 |  | 29 754 |  | 6 |  | 25 319 |  | 18 |
Established Brands |  |  |  |  |  |  |  |  |  |  |
Sandostatin |  | 1 238 |  | 1 413 |  | -12 |  | 1 439 |  | -2 |
Galvus Group |  | 859 |  | 1 092 |  | -21 |  | 1 199 |  | -9 |
Gleevec/Glivec |  | 745 |  | 1 024 |  | -27 |  | 1 188 |  | -14 |
Exforge Group |  | 743 |  | 901 |  | -18 |  | 980 |  | -8 |
Diovan Group |  | 652 |  | 773 |  | -16 |  | 1 003 |  | -23 |
Afinitor/Votubia |  | 512 |  | 938 |  | -45 |  | 1 083 |  | -13 |
Voltaren/Cataflam |  | 334 |  | 373 |  | -10 |  | 360 |  | 4 |
Zortress/Certican |  | 329 |  | 431 |  | -24 |  | 452 |  | -5 |
Exjade/Jadenu |  | 323 |  | 563 |  | -43 |  | 653 |  | -14 |
Neoral/Sandimmun(e) |  | 310 |  | 368 |  | -16 |  | 393 |  | -6 |
Contract manufacturing |  | 214 |  | 108 |  | 98 |  |  |  | nm |
Other |  | 3 641 |  | 4 257 |  | -14 |  | 4 944 |  | -14 |
Total Established Brands |  | 9 900 |  | 12 241 |  | -19 |  | 13 694 |  | -11 |
Total division net sales to third parties |  | 41 296 |  | 41 995 |  | -2 |  | 39 013 |  | 8 |
1 Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022
2 Net sales to third parties reflect Xolair sales for all indications.
Net sales of Top 20 products | Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022
Brands |  | Brand classification by therapeutic area, other promoted brands or established brands |  | Key indications |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology |  | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) |  | 2 770 |  | 2 018 |  | 4 788 |
Entresto |  | Cardiovascular |  | Chronic heart failure, hypertension |  | 2 354 |  | 2 290 |  | 4 644 |
Promacta/Revolade |  | Hematology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 1 083 |  | 1 005 |  | 2 088 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis (RMS) |  | 1 153 |  | 860 |  | 2 013 |
Tasigna |  | Hematology |  | Chronic myeloid leukemia (CML) |  | 877 |  | 1 046 |  | 1 923 |
Lucentis |  | Other Promoted Brands |  | Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) |  |  |  | 1 874 |  | 1 874 |
Tafinlar + Mekinist |  | Solid Tumors |  | BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication |  | 678 |  | 1 092 |  | 1 770 |
Jakavi |  | Hematology |  | Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) |  |  |  | 1 561 |  | 1 561 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 434 |  | 936 |  | 1 370 |
Xolair 1 |  | Immunology |  | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps |  |  |  | 1 365 |  | 1 365 |
Sandostatin |  | Established Brands |  | Carcinoid tumors, acromegaly |  | 800 |  | 438 |  | 1 238 |
Kisqali |  | Solid Tumors |  | HR+/HER2- metastatic breast cancer |  | 472 |  | 759 |  | 1 231 |
Ilaris |  | Immunology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) |  | 570 |  | 563 |  | 1 133 |
Kesimpta |  | Neuroscience |  | Relapsing-remitting multiple sclerosis (RRMS) |  | 921 |  | 171 |  | 1 092 |
Galvus Group |  | Established Brands |  | Type 2 diabetes |  |  |  | 859 |  | 859 |
Gleevec/Glivec |  | Established Brands |  | Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) |  | 205 |  | 540 |  | 745 |
Exforge Group |  | Established Brands |  | Hypertension |  | 14 |  | 729 |  | 743 |
Diovan Group |  | Established Brands |  | Hypertension |  | 55 |  | 597 |  | 652 |
Kymriah |  | Hematology |  | r/r pediatric and young adults acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) |  | 196 |  | 340 |  | 536 |
Afinitor/Votubia |  | Established Brands |  | Breast cancer/ tuberous sclerosis complex (TSC) |  | 171 |  | 341 |  | 512 |
Top 20 brands total |  |  |  |  |  | 12 753 |  | 19 384 |  | 32 137 |
Rest of portfolio |  |  |  |  |  | 3 146 |  | 6 013 |  | 9 159 |
Total division net sales to third parties |  |  |  |  |  | 15 899 |  | 25 397 |  | 41 296 |
1 Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021
Brands |  | Brand classification by therapeutic area, other promoted brands or established brands1 |  | Key indications |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology |  | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA) |  | 2 883 |  | 1 835 |  | 4 718 |
Entresto |  | Cardiovascular |  | Chronic heart failure |  | 1 712 |  | 1 836 |  | 3 548 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis (RMS) |  | 1 427 |  | 1 360 |  | 2 787 |
Lucentis |  | Other Promoted Brands |  | Age-related macular degeneration (AMD) |  |  |  | 2 160 |  | 2 160 |
Tasigna |  | Hematology |  | Chronic myeloid leukemia (CML) |  | 882 |  | 1 178 |  | 2 060 |
Promacta/Revolade |  | Hematology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 947 |  | 1 069 |  | 2 016 |
Tafinlar + Mekinist |  | Solid Tumors |  | BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC) |  | 606 |  | 1 087 |  | 1 693 |
Jakavi |  | Hematology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 1 595 |  | 1 595 |
Xolair 2 |  | Immunology |  | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps |  |  |  | 1 428 |  | 1 428 |
Sandostatin |  | Established Brands |  | Carcinoid tumors, acromegaly |  | 843 |  | 570 |  | 1 413 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 469 |  | 882 |  | 1 351 |
Galvus Group |  | Established Brands |  | Type 2 diabetes |  |  |  | 1 092 |  | 1 092 |
Ilaris |  | Immunology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) |  | 501 |  | 558 |  | 1 059 |
Gleevec/Glivec |  | Established Brands |  | Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) |  | 263 |  | 761 |  | 1 024 |
Afinitor/Votubia |  | Established Brands |  | Breast cancer/ tuberous sclerosis complex (TSC) |  | 521 |  | 417 |  | 938 |
Kisqali |  | Solid Tumors |  | HR+/HER2- metastatic breast cancer |  | 339 |  | 598 |  | 937 |
Exforge Group |  | Established Brands |  | Hypertension |  | 14 |  | 887 |  | 901 |
Diovan Group |  | Established Brands |  | Hypertension |  | 51 |  | 722 |  | 773 |
Kymriah |  | Hematology |  | r/r pediatric and young adults acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) |  | 230 |  | 357 |  | 587 |
Ultibro Group |  | Other Promoted Brands |  | Cronic obstructive pulmonary disease (COPD) |  |  |  | 584 |  | 584 |
Top 20 products total |  |  |  |  |  | 11 688 |  | 20 976 |  | 32 664 |
Rest of portfolio |  |  |  |  |  | 3 311 |  | 6 020 |  | 9 331 |
Total division net sales to third parties |  |  |  |  |  | 14 999 |  | 26 996 |  | 41 995 |
1 Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.
2 Net sales to third parties reflect Xolair sales for all indications.
Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020
Brands |  | Brand classification by therapeutic area, other promoted brands or established brands1 |  | Key indications |  | US USD m |  | Rest of world USD m |  | Total USD m |
Cosentyx |  | Immunology |  | Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA) |  | 2 516 |  | 1 479 |  | 3 995 |
Gilenya |  | Neuroscience |  | Relapsing multiple sclerosis (RMS) |  | 1 562 |  | 1 441 |  | 3 003 |
Entresto |  | Cardiovascular |  | Chronic heart failure |  | 1 277 |  | 1 220 |  | 2 497 |
Tasigna |  | Hematology |  | Chronic myeloid leukemia (CML) |  | 859 |  | 1 099 |  | 1 958 |
Lucentis |  | Other Promoted Brands |  | Age-related macular degeneration (AMD) |  |  |  | 1 933 |  | 1 933 |
Promacta/Revolade |  | Hematology |  | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) |  | 833 |  | 905 |  | 1 738 |
Tafinlar + Mekinist |  | Solid Tumors |  | BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC) |  | 569 |  | 973 |  | 1 542 |
Sandostatin |  | Established Brands |  | Carcinoid tumors, acromegaly |  | 837 |  | 602 |  | 1 439 |
Jakavi |  | Hematology |  | Myelofibrosis (MF), polycythemia vera (PV) |  |  |  | 1 339 |  | 1 339 |
Xolair 2 |  | Immunology |  | Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU) |  |  |  | 1 251 |  | 1 251 |
Galvus Group |  | Established Brands |  | Type 2 diabetes |  |  |  | 1 199 |  | 1 199 |
Gleevec/Glivec |  | Established Brands |  | Chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST) |  | 315 |  | 873 |  | 1 188 |
Afinitor/Votubia |  | Established Brands |  | Breast cancer/ tuberous sclerosis complex (TSC) |  | 644 |  | 439 |  | 1 083 |
Diovan Group |  | Established Brands |  | Hypertension |  | 124 |  | 879 |  | 1 003 |
Exforge Group |  | Established Brands |  | Hypertension |  | 16 |  | 964 |  | 980 |
Zolgensma |  | Neuroscience |  | Spinal muscular atrophy (SMA) |  | 459 |  | 461 |  | 920 |
Ilaris |  | Immunology |  | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD gout) |  | 400 |  | 473 |  | 873 |
Kisqali |  | Solid Tumors |  | HR+/HER2- metastatic breast cancer |  | 318 |  | 369 |  | 687 |
Exjade/Jadenu |  | Established Brands |  | Chronic iron overload |  | 138 |  | 515 |  | 653 |
Votrient |  | Solid Tumors |  | Renal cell carcinoma (RCC) |  | 259 |  | 376 |  | 635 |
Top 20 products total |  |  |  |  |  | 11 126 |  | 18 790 |  | 29 916 |
Rest of portfolio |  |  |  |  |  | 3 216 |  | 5 881 |  | 9 097 |
Total division net sales to third parties |  |  |  |  |  | 14 342 |  | 24 671 |  | 39 013 |
1 Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.
2 Net sales to third parties reflect Xolair sales for all indications.
Sandoz [member] |
Statement [line items] |
Net sales | Sandoz Division net sales to third parties by business franchise
|  | 2022 USD m |  | 2021 USD m |  | Change (2021 to 2022) USD % |  | 2020 USD m |  | Change (2020 to 2021) USD % |
Retail Generics 1 |  | 6 776 |  | 7 092 |  | -4 |  | 7 244 |  | -2 |
Biopharmaceuticals |  | 2 093 |  | 2 116 |  | -1 |  | 1 928 |  | 10 |
Anti-Infectives 1 |  | 380 |  | 423 |  | -10 |  | 474 |  | -11 |
Total division net sales to third parties |  | 9 249 |  | 9 631 |  | -4 |  | 9 646 |  | 0 |
1 Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_StatementLineItems
Namespace Prefix: | nvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |